Related Experiment Video
Updated: Jan 14, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Discontinuation of Long-acting Injectable Cabotegravir-Rilpivirine in a Large Clinic Cohort
Katerina A Christopoulos1, Xavier Erguera1, Janet Grochowski1
1Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Abstract:
Little is known about long-acting injectable cabotegravir-rilpivirine discontinuation outside clinical trials. In a large clinic cohort, 1 in 6 people with HIV discontinued long-acting injectable cabotegravir-rilpivirine over a median of ∼18 months. Injection-related pain was common. Virologic failure and efficacy concerns drove discontinuation for people with HIV with adherence challenges. Most had viral suppression on alternate antiretrovirals post-discontinuation.
More Related Videos
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Retrovirus Life Cycles
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Subviral Agents
Nonlinear Pharmacokinetics: Drug Elimination for IV Bolus Injection
Following the administration of a single intravenous (IV) bolus injection, we can determine the concentration of the drug in the plasma at any given time. This calculation is achieved using a specific equation that integrates the values of Vmax and KM.
We can also...
Retroviruses

